A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)

Trial Profile

A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2018

At a glance

  • Drugs APL 2 (Primary)
  • Indications Glomerulonephritis; IgA nephropathy; Kidney disorders; Lupus nephritis; Membranoproliferative glomerulonephritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 18 Apr 2018 Planned number of patients changed from 36 to 48.
    • 19 Mar 2018 According to an Apellis Pharmaceuticals media release, the company expected data from this study in the second half of 2018.
    • 07 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top